Infants younger than 1 year of age with rhabdomyosarcoma
- 15 December 1986
- Vol. 58 (12), 2606-2610
- https://doi.org/10.1002/1097-0142(19861215)58:12<2606::aid-cncr2820581209>3.0.co;2-t
Abstract
Of a total of 1561 patients registered in the Intergroup Rhabdomyosarcoma Study (IRS) as of May 1983, 78 patients (5%) were younger than 1 year of age. These infants did not differ from the older children (1–20 years of age) in male/female ratio, clinical grouping, or survival rates. Infants younger than 1 year of age had a significantly greater frequency of undifferentiated sarcoma, 18% versus 7% in older children (P versus 4% in older children (P versus 10% (P <0.05). In addition, infants tended to receive less of the prescribed doses of chemotherapy and radiation therapy than older children, and to develop more toxicity to treatment than older children. Despite these differences, the overall survival curve for the two age groups appears to be similar. In contrast to Wilms' tumor and neuroblastoma, in which age (<1 year) is a favorable prognostic factor, age does not appear to be an important prognostic factor in rhabdomyosarcoma.This publication has 4 references indexed in Scilit:
- The intergroup rhabdomyosarcoma study (NIH): Objectives and clinical staging classificationJournal of Pediatric Surgery, 1975
- Incidence of malignant tumors in U.S. childrenThe Journal of Pediatrics, 1975
- Prognosis in childhood rhabdomyosarcomaCancer, 1970
- Embryonal rhabdomyosarcoma.A clinicopathological studyCancer, 1964